Verified Nov 2026
Other
·
Atlanta, Georgia
·
Since 2006
VERO Biotech is a private biotechnology company headquartered in Atlanta, Georgia, founded in 2006 and reporting an estimated 200-500 employees and an estimated revenue band of $50-100M. Its flagship product, the GENOSYL® Delivery System, is an FDA-approved tankless device that generates inhaled nitric oxide on demand for patients with cardiopulmonary conditions. The company serves the healthcare sector, with its system used in neonatal intensive care units, acute care hospitals, operating rooms, and inter-hospital transport. Its most recent public item, a case study published by Forj Medical in July 2026, covers a third-generation version of the GENOSYL® system.
Vero Biotech at a glance
Revenue
$50-100M
Est. band
Employees
200-500
Founded
2006
Headquarters
Atlanta, Georgia
Import activity
11
Industries
Automotive
Electric Vehicles
Electronics
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
11
Named foreign suppliers
2
Top origins
Taiwan · China
Shared foreign counterparties do not establish that these companies buy from Vero Biotech.
What this tells a buyer
The record contains no customs or trade shipment data for the company, and its most recent reported development is a July 2026 GENOSYL® Gen 3 case study published by Forj Medical.
The company's product line centers on the GENOSYL® Delivery System, an FDA-approved, tankless inhaled nitric oxide platform, and it offers the Partnership365™ Service Program for customer support and clinical workflow training.
The company is privately held, with no public ticker, and its record lists no reported customers, no certifications, and no named ownership structure.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
VERO Biotech is a private biotechnology company headquartered in Atlanta, Georgia, founded in 2006 and reporting an estimated 200-500 employees and an estimated revenue band of $50-100M. Its flagship product, the GENOSYL® Delivery System, is an FDA-approved tankless device that generates inhaled nitric oxide on demand for patients with cardiopulmonary conditions. The company serves the healthcare sector, with its system used in neonatal intensive care units, acute care hospitals, operating rooms, and inter-hospital transport. Its most recent public item, a case study published by Forj Medical in July 2026, covers a third-generation version of the GENOSYL® system.
At a glance
Attribute | Detail |
|---|---|
Founded | 2006 |
Headquarters | Atlanta, Georgia |
Employees | 200-500 |
Revenue | $50-100M (estimated) |
What Vero Biotech makes
The company's product line centers on the GENOSYL® Delivery System, an FDA-approved, tankless inhaled nitric oxide platform, and it offers the Partnership365™ Service Program for customer support and clinical workflow training.
Products and capabilities described on the company's own site include LED (source: vero-biotech.com).
Trade and customs footprint
The record contains no customs or trade shipment data for the company, and its most recent reported development is a July 2026 GENOSYL® Gen 3 case study published by Forj Medical. US customs bill-of-lading records list 11 inbound shipments across 2 foreign suppliers, with top origins including Taiwan · China.
Latest developments
2026-07-20 — GENOSYL® Gen 3 Case Study: Forj Medical & Vero Biotech (forjmedical.com)
2026-03-22 — We are excited to exhibit here at the Society of Critical Care Congress in Chicago, IL. If you are here, be sure to stop by our VERO Biotech booth Look forward to … | VERO Biotech (linkedin.com)
2026-03-04 — Big News! Our website just got a major refresh. | VERO Biotech (linkedin.com)
2026-02-13 — Life Sciences News & Events | VERO Biotech (vero-biotech.com)
2025-11-18 — Excited to announce my new role at Vero Biotech! Thrilled to join the talented team and to contribute to enhanced patient care through advanced development initiatives. | Jeremy Hemingway, P.E. (linkedin.com)
2025-11-17 — We will be exhibiting at AARC Congress 2025 at the Phoenix Convention Center in Phoenix, AZ. Will you be there? Stop by our VERO Biotech booth Look forward to learning more about … | VERO Biotech (linkedin.com)
Company details
The company is privately held, with no public ticker, and its record lists no reported customers, no certifications, and no named ownership structure. Vero Biotech was founded in 2006, has an estimated 200-500 employees, and is headquartered in Atlanta, Georgia.
Frequently asked questions
What does Vero Biotech do?
VERO Biotech is a private biotechnology company headquartered in Atlanta, Georgia, founded in 2006 and reporting an estimated 200-500 employees and an estimated revenue band of $50-100M. Its flagship product, the GENOSYL® Delivery System, is an FDA-approved tankless device that generates inhaled nitric oxide on demand for patients with cardiopulmonary conditions. The company serves the healthcare sector, with its system used in neonatal intensive care units, acute care hospitals, operating rooms, and inter-hospital transport. Its most recent public item, a case study published by Forj Medical in July 2026, covers a third-generation version of the GENOSYL® system.
Where is Vero Biotech headquartered?
Vero Biotech is headquartered in Atlanta, Georgia (387 Technology Cir NW, Atlanta, Georgia, 30313).
When was Vero Biotech founded?
Vero Biotech was founded in 2006.
How big is Vero Biotech?
Vero Biotech has an estimated 200-500 employees, with revenue in the $50-100M range (estimated).
Does Vero Biotech import from overseas suppliers?
US customs bill-of-lading records show 11 inbound shipments for Vero Biotech, with top origins including Taiwan · China.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.